Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index

被引：20

作者：

Breccia, Massimo ^{[1
]}

Loglisci, Giuseppina ^{[1
]}

Salaroli, Adriano ^{[1
]}

Serrao, Alessandra ^{[1
]}

Alimena, Giuliana ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy

来源：

LEUKEMIA RESEARCH | 2012年 / 36卷 / 04期

关键词：

IMATINIB MESYLATE;

D O I：

10.1016/j.leukres.2011.12.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E66 / E67

页数：2

共 9 条

[1]

AICHBERGER KJ, 2011, AM J HEMATOL

[2]

[Anonymous], BLOOD

[3] Imatinib mesylate may improve fasting blood glucose in diabetic Ph plus chronic myelogenous leukemia patients responsive to treatment [J].

Breccia, M ;

Muscaritoli, M ;

Aversa, Z ;

Mandelli, F ;

Alimena, G .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4653-4655

[4]

Breccia M., 2007, LEUKEMIA RES, V31, P1765

[5] The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism [J].

Breccia, Massimo ;

Alimena, Giuliana .

LEUKEMIA RESEARCH, 2009, 33 (07) :871-875

[6] Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib [J].

Day, Elizabeth ;

Waters, Beatrice ;

Spiegel, Katrin ;

Alnadaf, Tanja ;

Manley, Paul W. ;

Buchdunger, Elisabeth ;

Walker, Christoph ;

Jarai, Gabor .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 599 (1-3) :44-53

[7] Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet [J].

Hagerkvist, Robert ;

Jansson, Leif ;

Welsh, Nils .

CLINICAL SCIENCE, 2008, 114 (1-2) :65-71

[8]

le Coutre P, 2007, BLOOD, V110

[9] Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes [J].

Mokhtari, Dariush ;

Welsh, Nils .

CLINICAL SCIENCE, 2010, 118 (3-4) :241-247

← 1 →